Volgen
Joost Besseling
Joost Besseling
Junior doctor in Internal Medicine, Amsterdam Medical Center, the Netherlands
Geverifieerd e-mailadres voor amc.nl
Titel
Geciteerd door
Geciteerd door
Jaar
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome
B Sjouke, DM Kusters, I Kindt, J Besseling, JC Defesche, EJG Sijbrands, ...
European heart journal 36 (9), 560-565, 2014
4482014
Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus
J Besseling, JJP Kastelein, JC Defesche, BA Hutten, GK Hovingh
JAMA 313 (10), 1029-1036, 2015
3692015
Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers
J Besseling, I Kindt, M Hof, JJP Kastelein, BA Hutten, GK Hovingh
Atherosclerosis 233 (1), 219-223, 2014
1932014
Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology
G De Backer, J Besseling, J Chapman, GK Hovingh, JJP Kastelein, ...
Atherosclerosis 241 (1), 169-175, 2015
1752015
Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality
J Besseling, GK Hovingh, R Huijgen, JJP Kastelein, BA Hutten
Journal of the American College of Cardiology 68 (3), 252-260, 2016
1562016
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
JJP Kastelein, J Besseling, S Shah, J Bergeron, G Langslet, GK Hovingh, ...
The Lancet 385 (9983), 2153-2161, 2015
1052015
Screening and treatment of familial hypercholesterolemia–Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014)
J Besseling, B Sjouke, JJP Kastelein
Atherosclerosis 241 (2), 597-606, 2015
462015
Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation …
J Besseling, JB Reitsma, D Gaudet, D Brisson, JJP Kastelein, GK Hovingh, ...
European heart journal 38 (8), 565-573, 2016
452016
Efficacy and safety of mipomersen sodium (Kynamro)
K Hovingh, J Besseling, J Kastelein
Expert opinion on drug safety 12 (4), 569-579, 2013
382013
LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?
J Besseling, J van Capelleveen, JJP Kastelein, GK Hovingh
Drugs 73 (4), 293-301, 2013
232013
Intestinal cholesterol secretion: future clinical implications
L Jakulj, J Besseling, ES Stroes, AK Groen
Neth J Med 71 (9), 459-465, 2013
212013
EUROASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of …
G De Backer, J Besseling, J Chapman, GK Hovingh, JJ Kastelein, ...
Atherosclerosis 241 (1), 169-175, 2015
182015
Homozygous autosomal dominant hypercholesterolemia in the Netherlands: prevalence, genotype-phenotype relationship and clinical outcome
B Sjouke, D Kusters, I Kindt, J Besseling, J Defesche, E Sijbrands, ...
Journal of the American College of Cardiology 63 (12 Supplement), A2050, 2014
182014
Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
ML Hartgers, J Besseling, ES Stroes, J Wittekoek, JHW Rutten, J de Graaf, ...
Journal of clinical lipidology 12 (4), 972-980. e1, 2018
152018
Clinical Phenotype in Relation to the Distance-to-index-patient in Familial Hypercholesterolemia
J Besseling, R Huijgen, SS Martin, BA Hutten, JJP Kastelein, GK Hovingh
Atherosclerosis 246, 1-6, 2016
102016
Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises
J Besseling, GK Hovingh, ES Stroes
Neth J Med 71 (3), 118-122, 2013
82013
Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study
J Besseling, J Reitsma, JA Van Erkelens, MHJ Schepens, MPC Siroen, ...
Cancers 13 (145), 2021
72021
Is there a link between diabetes and cholesterol metabolism?
J Besseling, BA Hutten
Expert review of cardiovascular therapy 14 (3), 259-261, 2016
62016
predicting the presence of a mutation resulting in familial hypercholesterolemia-development of a prediction model in a cohort of 64,000 subjects
J Besseling, JB Reitsma, GK Hovingh, BA Hutten
Circulation 130 (suppl_2), A16172-A16172, 2014
42014
Attainment of LDL-C treatment target in familial hypercholesterolemia patients: A theoretical model exploring efficacy of current and novel lipid lowering therapies
ML Hartgers, J Besseling, GK Hovingh
Atherosclerosis 252, e43-e44, 2016
32016
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20